Navigation Links
Xencor Reports Second Quarter 2014 Financial Results
Date:7/31/2014

MONROVIA, Calif., July 31, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the second quarter ended June 30, 2014 and provided a review of recent business highlights.

"In the second quarter, we presented preclinical data at the American Thoracic Society 2014 International Conference (ATS) demonstrating three novel mechanisms of action of XmAb®7195, in development for the treatment of asthma, and we are now enrolling patients in a Phase 1a clinical trial. Our bispecific antibody program has yielded several potential lead candidates that target the immune system to specific cancer cells and that show potential to overcome the dosing and manufacturing hurdles that have plagued earlier generation bispecifics," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. "The second half of this year is an exciting period for us as we approach preliminary data from both our XmAb®7195 and XmAb®5871 programs and selection of our lead bispecific for IND-enabling development."

Recent Business HighlightsXmAb7195

  • In May 2014, Xencor presented preclinical data on XmAb7195 at ATS demonstrating rapid IgE clearance by XmAb7195 compared to omalizumab. Results of the study found that after a single IV dose of XmAb7195 or omalizumab in chimpanzees, XmAb7195 reduced free IgE to at least 10-fold lower levels than omalizumab. In addition, XmAb7195 rapidly reduced free IgE levels to below quantifiable levels, until day 10. XmAb7195 depleted total IgE below quantifiable levels within one hour.
  • In May 2014, Xencor initiated a Phase 1a clinical trial of XmAb7195 in healthy subjects and all
    '/>"/>

  • SOURCE Xencor Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call
    2. Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer
    3. Xencor, Inc. Announces Closing of Initial Public Offering
    4. Pharmacyclics Reports Second Quarter 2014 Results
    5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
    6. Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015
    7. HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013
    8. Endo Reports Second Quarter Financial Results
    9. Columbia Laboratories Reports Second Quarter 2014 Financial Results
    10. Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
    11. Hospira Reports Second-Quarter 2014 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/29/2014)... SAN DIEGO , 29. ... Ltd. (nachstehend Daiichi Sankyo) (TSE: 4568) und ... gaben heute gemeinsam eine definitive Fusionsvereinbarung bekannt, ... von Ambit Biosciences für 15 US-Dollar je ... anschließenden Zusammenschluss mit einem Tochterunternehmen von Daiichi ...
    (Date:9/29/2014)... IRVING, Texas , Sept. 29, 2014 /PRNewswire/ ... 340B Drug Pricing Program, has announced that it ... Services Administration (HRSA) to continue serving in its ... 2019. Apexus, which has held this position for ... with more than 25,000 safety-net provider locations, drug ...
    (Date:9/29/2014)... SEATTLE , Sept. 29, 2014 ... leverages Next Generation Sequencing to profile the adaptive ... a Scientific Advisory Board to provide strategic and ... diagnostic suite of assays in the diagnosis and ... initial focus of the SAB will be to ...
    Breaking Medicine Technology:Daiichi Sankyo wird Ambit Biosciences übernehmen 2Daiichi Sankyo wird Ambit Biosciences übernehmen 3Daiichi Sankyo wird Ambit Biosciences übernehmen 4Daiichi Sankyo wird Ambit Biosciences übernehmen 5Daiichi Sankyo wird Ambit Biosciences übernehmen 6Daiichi Sankyo wird Ambit Biosciences übernehmen 7Daiichi Sankyo wird Ambit Biosciences übernehmen 8Apexus Wins HRSA Contract to Remain Prime Vendor of 340B Program 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 3
    ... RESEARCH TRIANGLE PARK, N.C., Oct. 16 Liquidia,Technologies ... founder,and University of North Carolina-Chapel Hill professor, Joseph ... DeSimone will discuss drug delivery,applications of the PRINT(TM) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20060614/CLW002LOGO ), -- ...
    ... went to see Dr. Peter Hersey, a medical oncologist ... was told he only had three,to six months to ... one,of the most difficult to treat forms of cancer. ... previously treated,area of his face and nothing was helping ...
    Cached Medicine Technology:Targeted Nanoparticles Offer Promise in the Battle Against Cancer 2Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years 2
    (Date:9/30/2014)... 2014 From October 12-15, MMS, ... the 2014 SHSMD Connections Annual Conference in San Diego, ... & Market Development (SHSMD) is proud to host the ... and communications, and strategic planning professionals in San Diego ... , The conference is a four-day event designed ...
    (Date:9/30/2014)... IN (PRWEB) September 30, 2014 ... Ron Receveur encourages all persons who have received dental ... in a recent blog post. , The post, which ... with dental implants that if they don’t brush and ... same way people lose their natural teeth: the bone ...
    (Date:9/30/2014)... “Biology and botany are having an ... it’s about naming rights.” , In Homeostasis: ... the Bryan William Brickner Blog, the focus is ... Health (PubMed). The post highlights five cannabinoid system ... aging with THC, the wake-inducing effects of CBD, ...
    (Date:9/30/2014)... September 30, 2014 Named a ... East Longmeadow facility has officially announced that they ... that combines advanced medical technology with supportive, ... one of the only non-hospital options available in ... The primary focus of this Ventilator Program ...
    (Date:9/30/2014)... (PRWEB) September 30, 2014 American Medical ... a collaborative agreement to raise awareness about Alzheimer’s disease ... IDs for people with these brain disorders. , American ... generated by AFA to the foundation to support its ... their families. The ID bracelets and necklaces can be ...
    Breaking Medicine News(10 mins):Health News:MMS, Inc. (Medical Marketing Service) to Attend the 2014 SHSMD Connections Annual Conference in October 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 3Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 2Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 3
    ... study by a Swedish researcher on the effects of the ... likely to occur when they have their period. The// researcher ... fluctuations causing the levels of relaxin (a hormone which relaxes ... studied for the research and it was seen that women ...
    ... from fatty foods that we eat. A certain amount// of cholesterol ... keep the body healthy but a high level can lead to ... a build up of small fatty lumps developing on the inside ... are at greater risk if we smoke, have high blood pressure ...
    ... a press release the Ministry of Health has indicated the current ... on Dengue// the Ministry has confirmed reports of 9453 cases ... upto 12 .30 hrs. ,In Delhi and NCR - ... of 2872 cases and 59 deaths have been reported from Delhi, ...
    ... access to a high-profile detainee at Guantanamo Bay, Cuba, ... secrets" whose revelation could "cause extremely grave damage", the ... at secret CIA prisons must not be allowed to ... even to their lawyers, the Post reported.,A lawyer at ...
    ... medical problems and surgeries in space before astronauts start moving ... a person develops a problem say, in Mars? He or ... time simply because it takes over three years to reach ... little difference in the dose of general anesthesia needed to ...
    ... industry which has been simmering in the trans-fat controversy for ... their sticky ally- the hydrogenated// vegetable oils! This is perhaps ... & Spencer, Asda, Sainsbury’s and Tesco have already communicated their ... British Medical Journal has urged the Government to bring in ...
    Cached Medicine News:Health News:Researchers explore medicine in space 2Health News:Researchers explore medicine in space 3
    Full Handle Laseredge Crescent Blade Knife, angled double bevel. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
    Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
    Full Handle Laseredge Stab Blade Knife, 45 blade. Blade tip dimension: 8.9 mm x 1.9 mm x 1.9 mm....
    Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 3 mm x 1.0 mm x 3.0 mm....
    Medicine Products: